About
Prism BioLab develops proprietary small-molecule peptidomimetics (PepMetics®) to target previously 'undruggable' protein–protein interactions, focusing on indications such as oncology, cirrhosis and gastrointestinal disorders. Its approach uses a library that mimics α‑helix and β‑turn peptide motifs and includes programs such as PRI724 and E7386 (CBP/β‑catenin inhibitors) which have been licensed to partners.
Explore Prism BioLab's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.